Who are Aflibercept (Regeneron, USA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aflibercept Injection [Eylea].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aflibercept-regeneron-usa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aflibercept (Regeneron, USA) — Competitive Intelligence Brief

Aflibercept (Regeneron, USA) (Aflibercept (Regeneron, USA)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (soluble decoy receptor). Area: Oncology, Ophthalmology.

phase 3 VEGF inhibitor (soluble decoy receptor) VEGF-A, VEGF-B, PlGF (Placental Growth Factor) Oncology, Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

Aflibercept (Regeneron, USA) (Aflibercept (Regeneron, USA)) — Cinnagen. Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aflibercept (Regeneron, USA) TARGET	Aflibercept (Regeneron, USA)	Cinnagen	phase 3	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (soluble decoy receptor) class)

Caregen Co. Ltd. · 1 drug in this class
Cinnagen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aflibercept (Regeneron, USA) — Competitive Intelligence Brief. https://druglandscape.com/ci/aflibercept-regeneron-usa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab